| PI3Kγ is a molecular switch that controls immune suppression MM Kaneda, KS Messer, N Ralainirina, H Li, CJ Leem, S Gorjestani, ... Nature 539 (7629), 437-442, 2016 | 1027 | 2016 |
| Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells O De Henau, M Rausch, D Winkler, LF Campesato, C Liu, DH Cymerman, ... Nature 539 (7629), 443-447, 2016 | 769 | 2016 |
| Diverse cellular and organismal functions of the lysosomal thiol reductase GILT MP Rausch, KT Hastings Molecular immunology 68 (2), 124-128, 2015 | 77 | 2015 |
| IL-27 and TCR stimulation promote T cell expression of multiple inhibitory receptors JH DeLong, A O’Hara Hall, M Rausch, D Moodley, J Perry, J Park, ... Immunohorizons 3 (1), 13-25, 2019 | 71 | 2019 |
| Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application MP Rausch, KT Hastings Exon Publications, 121-142, 2017 | 60 | 2017 |
| GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1 MP Rausch, KR Irvine, PA Antony, NP Restifo, P Cresswell, KT Hastings The Journal of Immunology 185 (5), 2828-2835, 2010 | 57 | 2010 |
| An orally active small molecule TGF-β receptor I antagonist inhibits the growth of metastatic murine breast cancer MP Rausch, T Hahn, L Ramanathapuram, D Bradley-Dunlop, ... Anticancer research 29 (6), 2099-2109, 2009 | 55 | 2009 |
| Correction: corrigendum: PI3Kγ is a molecular switch that controls immune suppression MM Kaneda, KS Messer, N Ralainirina, H Li, CJ Leem, S Gorjestani, ... Nature 542 (7639), 124-124, 2017 | 38 | 2017 |
| GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1 MP Rausch, KT Hastings Journal of investigative dermatology 132 (1), 154-162, 2012 | 37 | 2012 |
| A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity MP Rausch, AR Sertil International reviews of immunology 34 (2), 104-122, 2015 | 20 | 2015 |
| IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma T Aghayev, AM Mazitova, JR Fang, IO Peshkova, M Rausch, M Hung, ... Cancer discovery 12 (8), 1960-1983, 2022 | 18 | 2022 |
| An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen MP Rausch, KT Hastings PloS one 10 (4), e0123332, 2015 | 18 | 2015 |
| Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated … M Rausch, J Hua, D Moodley, KF White, KH Walsh, CE Miller, G Tan, ... Cancer Research 80 (16_Supplement), 4550-4550, 2020 | 10 | 2020 |
| MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys KF White, M Rausch, J Hua, KH Walsh, CE Miller, CC Wells, D Moodley, ... Cancer Research 79 (13_Supplement), 558-558, 2019 | 10 | 2019 |
| GILT in thymic epithelial cells facilitates central CD4 T cell tolerance to a tissue-restricted, melanoma-associated self-antigen MP Rausch, LR Meador, TC Metzger, H Li, S Qiu, MS Anderson, ... The Journal of Immunology 204 (11), 2877-2886, 2020 | 8 | 2020 |
| Innate and adaptive immune responses to cancer KT Hastings, MP Rausch Fundamentals of Cancer Prevention, 81-121, 2013 | 8 | 2013 |
| Cutaneous melanoma NH Matthews, WQ Li, AA Qureshi, MA Weinstock, E Cho, M Norval, ... Etiology and Therapy, 2017, 2017 | 6 | 2017 |
| Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models O De Henau, T Merghoub, D Winkler, S Sharma, M Pink, J Tchaicha, ... Cancer Research 76 (14_Supplement), 554-554, 2016 | 5 | 2016 |
| Abstract B029: The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in … J Kutok, J Ali, E Brophy, A Castro, J DiNitto, C Evans, K Faia, S Goldstein, ... Cancer Immunology Research 4 (1_Supplement), B029-B029, 2016 | 5 | 2016 |
| SRF617 is a potent inhibitor of CD39 with immunomodulatory and antitumor properties MC Warren, S Matissek, M Rausch, M Panduro, RJ Hall, A Dulak, ... ImmunoHorizons 7 (5), 366-379, 2023 | 4 | 2023 |
